Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Multiple Myeloma

Multiple Myeloma Medicines in India: Imported Options for New and Relapsed Disease

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERMultiple myeloma is a blood cancer of plasma cells, the antibody-making cells that sit inside the bone marrow. As the abnormal cells multiply they weaken bone, crowd out healthy blood cells and release a protein that can harm the kidneys. GLOBOCAN estimates 17,529 new cases in India in 2024 [1]. Treatment choice depends on whether the disease is newly found or has relapsed, which drug classes have already been used, and whether a stem cell transplant is planned. Named Patient Program (NPP) can bring in each of the 12 medicines below for one named patient, once the treating hematologist writes the prescription.
17,529
new multiple myeloma diagnoses in India during 2024, with 13,255 deaths from the disease
Source: IARC GLOBOCAN 2024 [1]
8.9%
of the world's new myeloma cases were in India: 17,529 out of 196,157
Source: GLOBOCAN 2024 [1, 2]
70%
of 696 patients at a North Indian referral centre were already at ISS stage III when first seen
Source: JCO Glob Oncol, 2021 [3]
12.07 months
median wait from diagnosis to stem cell transplant at a Kerala cancer centre, about double the Western figure
Source: Indian J Hematol Blood Transfus, 2026 [4]

How myeloma shows itself: bones, blood, kidneys and calcium

Many people first see an orthopaedic surgeon for back pain, a kidney specialist for rising creatinine, or a physician for anaemia that does not settle. Doctors use the short form CRAB for the four classic warning signs. The table links each sign to what Indian hospitals have recorded.

SignWhy it happensWhat Indian data show
Bone damageMyeloma cells switch on bone-dissolving cells, causing pain, thin spots (lytic lesions) and fracturesBone lesions were found in 92.6% of 110 patients aged 40 or under at Tata Memorial Centre [5]
AnaemiaThe marrow fills with plasma cells and makes fewer red cells, so tiredness and breathlessness followIn a North Indian series of 696 patients, anaemia at diagnosis was the one CRAB feature that still predicted shorter survival after adjustment [3]
Kidney damageFree light chains made by the cancer clog the kidney tubulesIn Jaipur, half of the patients who arrived with kidney failure reached a complete renal response by six months, and 4 of 6 on dialysis came off it [6]
High calciumCalcium leaks from damaged bone into the blood, giving thirst, constipation and confusionSeen in 11.9% of the young Tata Memorial group [5]

Repeated chest or urine infections are a fifth clue that is easily missed. In a 2026 national survey of Indian nephrologists, only half named recurrent infection as a myeloma feature [7].

How common is multiple myeloma in India?

For 2024, GLOBOCAN counts 17,529 new myeloma cases in India (22nd among all cancers) and 13,255 deaths (18th). About 39,313 people were living within five years of their diagnosis [1].

The worldwide figure is 196,157 new cases, and Asia accounts for 81,520 of them [2]. India's portion is 17,529 ÷ 196,157 = 8.9% of the world total and 17,529 ÷ 81,520 = 21.5% of Asia's.

Myeloma is mostly a disease of later life. The median age was 65.9 years in the North Indian series [3] and 52 years among 438 people given a transplant at AIIMS, New Delhi [8]. At Tata Memorial Centre, 110 of 1,980 newly diagnosed patients (5.5%) were 40 or younger [5]. In Kolkata, FISH testing of 280 new patients found a chromosome change in 51.07%, with deletion 13q the most frequent [9].

What treatment results look like in Indian hospitals

  • Survival in routine care. Real-time records of 696 North Indian patients showed 94% alive at one year, 87.5% at three years and 83.1% at five years [3].
  • Transplant still adds a lot. Among the young Tata Memorial patients, five-year progression-free survival was 58.5% with an autologous transplant and 27.8% without one [5]. In 76 high-risk patients at Rajiv Gandhi Cancer Institute, Delhi, estimated three-year survival was 74.7% after transplant against 52.9% without [10].
  • Long survivors exist. Of 438 AIIMS transplant patients treated between 1995 and 2019, 96 (21.9%) were alive ten years or more later [8].
  • Delays are common. At Malabar Cancer Centre only 12.8% of 86 transplant patients reached transplant after the advised three to four induction cycles; hospital waiting time (55%) and money (23%) were the main reasons [4].
  • Age alone should not rule out transplant. A Bengaluru review of 81 patients found about 80% of those over 65 fit for transplant by standard scores, yet only 14.8% of them received one, against 38.9% of younger patients [11].
  • Antibody treatment after relapse. A 139-patient phase IV study of single-agent daratumumab at Indian centres reported a 26.3% response rate and stable disease in 62.7% of patients [12].

Which imported medicine fits which stage

Myeloma labels are written around treatment history: how many earlier lines were given, and which drug classes the disease has stopped responding to. Use this table to see where each medicine below is approved; your hematologist confirms the fit.

SituationMedicines on this page
Newly diagnosed, transplant plannedDarzalex (with bortezomib, thalidomide and dexamethasone)
Newly diagnosed, no transplantDarzalex (with lenalidomide-dexamethasone, or bortezomib-melphalan-prednisone); Sarclisa (with bortezomib, lenalidomide and dexamethasone)
Relapse after one or more earlier linesDarzalex, Ninlaro, Xpovio or Nexpovio (with bortezomib), Felzartamab; Sarclisa or Darzalex with carfilzomib after 1 to 3 lines; Empliciti after 1 to 3 therapies
Relapse after two or more earlier linesBlenrep (with bortezomib, once a proteasome inhibitor and an immunomodulatory drug have been used); Empliciti, Sarclisa or Darzalex with pomalidomide (once lenalidomide and a proteasome inhibitor have been used); Aponermin (with thalidomide)
Four or more earlier lines, triple-class exposedElrexfio, Talvey, Xpovio or Nexpovio (with dexamethasone)
Tablets of melphalan not suitableAlkeran injection

"Triple-class" means the patient has already received a proteasome inhibitor (such as bortezomib), an immunomodulatory drug (such as lenalidomide) and an anti-CD38 antibody. Elrexfio and Talvey begin with small step-up doses; their US labels ask for a hospital stay after these early doses since cytokine release syndrome, a strong immune reaction, can follow them. Blenrep carries a boxed warning for eye damage, and its label calls for an eye examination before every dose.

Imported multiple myeloma medicines by type

All 12 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Darzalex (daratumumab)
Darzalex
daratumumab · IV infusion
Anti-CD38 antibody used at many stages: in newly diagnosed adults, with or without a planned transplant, in lenalidomide- or bortezomib-based combinations; at relapse together with lenalidomide, bortezomib, carfilzomib or pomalidomide; and on its own after three or more earlier lines
Anti-CD38 antibody US FDA
Sarclisa (isatuximab)
Sarclisa
isatuximab · IV infusion
Anti-CD38 antibody added to bortezomib, lenalidomide and dexamethasone for new patients not going for transplant; to carfilzomib-dexamethasone after one to three lines; or to pomalidomide-dexamethasone after two or more therapies that included lenalidomide and a proteasome inhibitor
Anti-CD38 antibody US FDA
Felzartamab (felzartamab)
Felzartamab
felzartamab · IV infusion
Anti-CD38 antibody taken with lenalidomide and dexamethasone by adults whose myeloma returned after at least one earlier line (first approved in China, August 2026)
Anti-CD38 antibody China NMPA
Blenrep (belantamab mafodotin)
Blenrep
belantamab mafodotin · IV infusion
BCMA-directed antibody-drug conjugate, combined with bortezomib and dexamethasone, for adults whose relapsed or resistant myeloma has already had two or more lines, among them a proteasome inhibitor and an immunomodulatory drug
BCMA or GPRC5D targeted US FDA
Elrexfio (elranatamab)
Elrexfio
elranatamab · Subcutaneous injection
BCMA x CD3 bispecific antibody for adults with relapsed or resistant myeloma after four or more lines that covered a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody (accelerated approval)
BCMA or GPRC5D targeted US FDA (accelerated approval)
Talvey (talquetamab)
Talvey
talquetamab · Subcutaneous injection
GPRC5D x CD3 bispecific antibody for adults whose myeloma persists or returns after four or more lines including all three main drug classes (accelerated approval)
BCMA or GPRC5D targeted US FDA
Ninlaro (ixazomib)
Ninlaro
ixazomib · Capsule
Proteasome inhibitor taken by mouth with lenalidomide and dexamethasone once at least one earlier therapy has been given; the label advises against it for maintenance or newly diagnosed disease outside trials
Proteasome inhibitor US FDA
Empliciti (elotuzumab)
Empliciti
elotuzumab · IV infusion
SLAMF7 antibody added to lenalidomide-dexamethasone after one to three earlier therapies, or to pomalidomide-dexamethasone after two or more, including lenalidomide and a proteasome inhibitor
Other targeted US FDA
Xpovio (selinexor)
Xpovio
selinexor · Tablet
Nuclear export (XPO1) blocker: once weekly with bortezomib and dexamethasone after one or more earlier therapies, or with dexamethasone alone when the disease resists two proteasome inhibitors, two immunomodulatory drugs and an anti-CD38 antibody after four or more therapies
Other targeted US FDA
Nexpovio (selinexor)
Nexpovio
selinexor · Tablet
European and UK brand of selinexor, approved for the same two myeloma combinations as Xpovio: with bortezomib-dexamethasone, or with dexamethasone in heavily treated, multi-resistant disease
Other targeted EMA (Europe)
Aponermin (aponermin)
Aponermin
aponermin · IV infusion
Engineered TRAIL protein that switches on the DR4/DR5 self-destruct signal in myeloma cells, given with thalidomide and dexamethasone after two or more earlier systemic treatments (approved in China, November 2023)
Other targeted China NMPA
Alkeran (melphalan)
Alkeran
melphalan · IV injection
Melphalan given into a vein for palliative treatment of myeloma when melphalan tablets taken by mouth are not appropriate
Chemotherapy US FDA

Compare all 12 multiple myeloma medicines

MedicineGeneric nameMultiple myeloma typeFormApproved by
DarzalexdaratumumabAnti-CD38 antibodyIV infusionUS FDA
SarclisaisatuximabAnti-CD38 antibodyIV infusionUS FDA
FelzartamabfelzartamabAnti-CD38 antibodyIV infusionChina NMPA
Blenrepbelantamab mafodotinBCMA or GPRC5D targetedIV infusionUS FDA
ElrexfioelranatamabBCMA or GPRC5D targetedSubcutaneous injectionUS FDA (accelerated approval)
TalveytalquetamabBCMA or GPRC5D targetedSubcutaneous injectionUS FDA
NinlaroixazomibProteasome inhibitorCapsuleUS FDA
EmplicitielotuzumabOther targetedIV infusionUS FDA
XpovioselinexorOther targetedTabletUS FDA
NexpovioselinexorOther targetedTabletEMA (Europe)
AponerminaponerminOther targetedIV infusionChina NMPA
AlkeranmelphalanChemotherapyIV injectionUS FDA

Reports to keep ready before the prescription

ReportWhat it tells the doctor
Serum protein electrophoresis, immunofixation and free light chainsMeasures the abnormal protein (M-protein) that tracks how active the myeloma is
Bone marrow biopsy with FISHConfirms the plasma cell count and shows high-risk changes such as del(17p) or 1q gain
PET-CT, low-dose whole-body CT or MRIMaps bone lesions and any disease outside the marrow
Creatinine, calcium and complete blood countShows kidney function, calcium level and anaemia before each new medicine
Full treatment historyLists every earlier regimen and whether the disease became resistant to it, which decides label eligibility

If you are starting Darzalex or Sarclisa, tell the blood bank. These antibodies stick to red cells and make routine cross-match tests look positive. A transfusion team at a Kolkata hospital found this in all 43 daratumumab-treated patients they tested and solved it with a low-strength DTT method in the lab [13].

Getting the permit, the delivery and help with cost

Every consignment is tied to one patient. The application goes to CDSCO on Form 12A in the patient's name, prepared for them by our pharmacist, and the approval comes back as a Form 12B permit. Our Form 12A and 12B guide explains each paper involved.

Antibody infusions and injections such as Darzalex, Sarclisa, Elrexfio and Talvey are given in hospital, so we normally deliver them cold-chain to the hospital pharmacy where the patient is treated; see delivery to hospitals in India. Ninlaro capsules and Xpovio or Nexpovio tablets are taken at home.

Myeloma care runs for years, and a South Asian survey of doctors found patients paying an average of 70% of their treatment costs out of their own pocket [14]. A 2026 review co-written by AIIMS, New Delhi doctors also notes that the newest immunotherapies are largely out of reach in lower-income settings [15]. Before treatment starts, check the manufacturer schemes collected under patient support and access programs.

How to get these multiple myeloma medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about multiple myeloma

References

  1. IARC Global Cancer Observatory. GLOBOCAN 2024 – India fact sheet (September 2026). https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf
  2. IARC Global Cancer Observatory. GLOBOCAN 2024 – Multiple myeloma fact sheet. https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf
  3. Yanamandra U et al. Survival outcomes of newly diagnosed multiple myeloma at a tertiary care center in North India (IMAGe: 001A study). JCO Glob Oncol. 2021;7:704-715. https://pubmed.ncbi.nlm.nih.gov/33999651/
  4. Menon A et al. Time to autologous stem cell transplant in multiple myeloma patients: a real-world single centre experience from India. Indian J Hematol Blood Transfus. 2026;42(5):1748-1753. https://pubmed.ncbi.nlm.nih.gov/42712629/
  5. John G et al. Multiple myeloma in young adults – insights from a tertiary care cancer centre in India. EJHaem. 2025;6(6):e70187. https://pubmed.ncbi.nlm.nih.gov/41384226/
  6. Vasant JS et al. Clinical outcomes of patients with multiple myeloma presenting with renal failure. South Asian J Cancer. 2025;14(3):632-635. https://pubmed.ncbi.nlm.nih.gov/41445879/
  7. Yanamandra U et al. Knowledge, awareness, and practice patterns of nephrologists in multiple myeloma (MIND-MM study). Clin Lymphoma Myeloma Leuk. 2026;26(9):e1093-e1103. https://pubmed.ncbi.nlm.nih.gov/42471300/
  8. Kumar L et al. Characteristics of long term survivors of multiple myeloma after autologous stem cell transplantation. Lancet Reg Health Southeast Asia. 2025;42:100680. https://pubmed.ncbi.nlm.nih.gov/41216175/
  9. Jha K, Saha S, Bhattacharyya M. Cytogenetic alterations and correlation with age and gender in patients of multiple myeloma from Eastern India. South Asian J Cancer. 2024;13(2):126-131. https://pubmed.ncbi.nlm.nih.gov/38919660/
  10. Soni A et al. Real world outcome of high-risk multiple myeloma: an Indian tertiary care centre experience. Clin Lymphoma Myeloma Leuk. 2025;25(2):e110-e119. https://pubmed.ncbi.nlm.nih.gov/39426943/
  11. Revannasiddaiah S et al. The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India. J Egypt Natl Canc Inst. 2022;34(1):21. https://pubmed.ncbi.nlm.nih.gov/35570260/
  12. Kumar L et al. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study. Future Oncol. 2024;20(4):191-205. https://pubmed.ncbi.nlm.nih.gov/38116642/
  13. Das SS et al. Resolving daratumumab-induced serologic interference: a modified low-concentration DTT protocol in multiple myeloma patients in Eastern India. Indian J Hematol Blood Transfus. 2026;42(5):1742-1747. https://pubmed.ncbi.nlm.nih.gov/42712821/
  14. Yanamandra U et al. Treatment accessibility, availability, and healthcare costs for multiple myeloma in South Asian countries. Clin Lymphoma Myeloma Leuk. 2025;25(12):e1134-e1144. https://pubmed.ncbi.nlm.nih.gov/41038751/
  15. Roy PG et al. Multiple myeloma management in a large low- and middle-income country: lessons from India. JCO Oncol Pract. 2026 (online ahead of print). https://pubmed.ncbi.nlm.nih.gov/41525508/
  16. US FDA prescribing information for each US-approved medicine (DailyMed). https://dailymed.nlm.nih.gov/dailymed/

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Multiple Myeloma Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP